Etanercept in moderate rheumatoid arthritis: PRESERVE study results from central/eastern Europe, Latin America and Asia. (October 2014)

• Record Type: Journal Article
• Authors: Pavelka, Karel; Burgos-Vargas, Ruben; Miranda, Pedro; Guzman, Renato; Yen, Jeng-Hsien; Izzi, Mustafa Al; Szekanecz, Zoltan; Tang, Boxiong; Szumski, Annette; Kotak, Sameer; Bananis, Eustratios; Koenig, Andrew S; Mahgoub, Ehab Y; Rahman, Mahboob U
• Is Part Of: International journal of clinical rheumatology. Volume 9:Number 5(2014)
• Page Start: 415
• Page End: 430
• Publication Date: 2014-10
• Subjects: biologic -- efficacy -- etanercept -- low disease activity -- methotrexate -- moderate rheumatoid arthritis -- remission; Rheumatology -- Periodicals; 616.723005
• DOI: 10.2217/ijr.14.27
• Languages: English
• ISSNs: 1758-4272

Abstract

Aims: We compared etanercept 50 mg once weekly (ETN50)/methotrexate versus etanercept 25 mg (ETN25)/methotrexate or biologic-free methotrexate after response to ETN50/methotrexate in moderate rheumatoid arthitis patients from central/eastern Europe, Latin America and Asia.Methods: In a 36-week induction phase, methotrexate-resistant patients received ETN50/methotrexate. In a 52-week, double-blind phase, patients who achieved sustained Disease Activity Score in 28 joints low disease activity (LDA) were randomized to ETN50/methotrexate, ETN25/methotrexate or methotrexate.Results: Sustained Disease Activity Score in 28 joints LDA was achieved in 85% at week 36. LDA was achieved in 83, 81 and 50% with ETN50/methotrexate, ETN25/methotrexate and methotrexate and remission in 66, 61 and 31%, respectively, at week 88 (p < 0.0001).Conclusion: Etanercept/methotrexate therapy for 36 weeks effectively induced response in this moderate rheumatoid arthritis subpopulation. Conventional- and reduced-dose etanercept/methotrexate was significantly more effective over the subsequent 52 weeks than biologic-free therapy.